Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 11, 2026HistopathologyOpen Access

Consistency of c‐Met protein overexpression over time in patients with non‐squamous non‐small cell lung cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

ACAlexis B. CortotRDRomain DuboisVGV. Grégoire

Discussion

Loading...

Member takes

Overview

Retrospective study assesses c-Met overexpression consistency in non-squamous NSCLC, indicating its reliability as a biomarker.

Key Points

  • The study aims to evaluate the consistency of c-Met protein overexpression in patients with non-squamous NSCLC over time.
  • Retrospective analysis of 160 patients with two or more longitudinal biopsy samples.
  • Assessment of c-Met protein expression before and after treatment.
  • Comparison of concordance rates for c-Met expression between biopsy samples.
  • The concordance rate for c-Met protein overexpression was 81.3%.
  • Patients with EGFR mutations demonstrated a lower concordance rate of 65.8%.
  • Fourteen patients with high discordance had frequent oncogenic driver alterations and previously received targeted therapy.

Cite This Study

Cortot et al. (2026) studied this question.

synapsesocial.com/papers/6a2a512e80c8f91e7f39d8dbhttps://doi.org/10.1111/his.70168
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prevalence, molecular characterization, and prognosis of c-Met protein overexpression in a real-world cohort of patients with non-squamous non-small cell lung cancer2025
  2. 2Clinical significance of c-Met expression in patients with advanced gastroesophageal adenocarcinoma.2026
  3. 3c-MET Overexpression Drives AKT Activation, and Combined Inhibition Synergistically Enhances Therapeutic Sensitivity in Non-Small-Cell Lung Cancer2026
  4. 4MET Overexpression Is Associated with Superior Immunotherapy Benefit in Advanced Non-Small Cell Lung Cancer2025
  5. 5MET Overexpression Is Associated with Superior Immunotherapy Benefit in Advanced Non-Small Cell Lung Cancer2025